Literature DB >> 34209585

A New Classification of the Severity of Psoriasis: What's Moderate Psoriasis?

Laura Salgado-Boquete1, José Manuel Carrascosa2, Mar Llamas-Velasco3, Ricardo Ruiz-Villaverde4, Pablo de la Cueva5, Isabel Belinchón6.   

Abstract

The purpose of this study is to propose a ranking system for the severity of psoriasis. The consensus method of selecting the indices to include and the classification of real patient profiles by an expert panel to create a gold standard of severity were used. The performance of potential cut-offs was evaluated to create a ranking algorithm. The combined use of PASI, BSA, and sPGA may allow the classification of the severity of psoriatic patients. The final algorithm identifies severe patients in a single step (2 out 3 are met: PASI ≥ 11 or BSA ≥ 10 or sPGA ≥ 3), while two steps are required for mild ((2 out 3 are met: PASI ≤ 3 or BSA ≤ 5 or sPGA ≤ 2) and DLQI < 5) and moderate forms (the patient does not meet 2 out 3 (PASI ≥ 11 or BSA ≥ 10 or sPGA ≥ 3) but has a DLQI ≥ 5. A ranking algorithm is presented, consisting of different measures of disease which classifies psoriatic patients into three categories: mild, moderate, and severe.

Entities:  

Keywords:  classification; cut-offs; discrimination; moderate; psoriasis; severity

Year:  2021        PMID: 34209585     DOI: 10.3390/life11070627

Source DB:  PubMed          Journal:  Life (Basel)        ISSN: 2075-1729


  22 in total

Review 1.  The psychosocial burden of psoriasis.

Authors:  Alexa B Kimball; Christine Jacobson; Stefan Weiss; Mary G Vreeland; Ying Wu
Journal:  Am J Clin Dermatol       Date:  2005       Impact factor: 7.403

2.  Emerging role of anti-IL23 in the treatment of psoriasis: When humanized is very promising.

Authors:  Annunziata Dattola; Martina Silvestri; Federica Tamburi; Giuseppe F Amoruso; Luigi Bennardo; Steven P Nisticò
Journal:  Dermatol Ther       Date:  2020-11-10       Impact factor: 2.851

3.  Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?

Authors:  G G Krueger; S R Feldman; C Camisa; M Duvic; J T Elder; A B Gottlieb; J Koo; J G Krueger; M Lebwohl; N Lowe; A Menter; W L Morison; J H Prystowsky; J L Shupack; J R Taylor; G D Weinstein; T L Barton; T Rolstad; R M Day
Journal:  J Am Acad Dermatol       Date:  2000-08       Impact factor: 11.527

Review 4.  Moderate Psoriasis: A Proposed Definition.

Authors:  M Llamas-Velasco; P de la Cueva; J Notario; L Martínez-Pilar; A Martorell; D Moreno-Ramírez
Journal:  Actas Dermosifiliogr       Date:  2017-08-17

5.  Defining and treating moderate plaque psoriasis: a dermatologist survey.

Authors:  Melissa L F Knuckles; Eugenia Levi; Jennifer Soung
Journal:  J Dermatolog Treat       Date:  2018-03-22       Impact factor: 3.359

6.  National Psoriasis Foundation clinical consensus on disease severity.

Authors:  David M Pariser; Jerry Bagel; Joel M Gelfand; Neil J Korman; Christopher T Ritchlin; Bruce E Strober; Abby S Van Voorhees; Melodie Young; Sheila Rittenberg; Mark G Lebwohl; Elizabeth J Horn
Journal:  Arch Dermatol       Date:  2007-02

7.  2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Authors:  Lisa G Rider; Rohit Aggarwal; Angela Pistorio; Nastaran Bayat; Brian Erman; Brian M Feldman; Adam M Huber; Rolando Cimaz; Rubén J Cuttica; Sheila Knupp de Oliveira; Carol B Lindsley; Clarissa A Pilkington; Marilynn Punaro; Angelo Ravelli; Ann M Reed; Kelly Rouster-Stevens; Annet van Royen-Kerkhof; Frank Dressler; Claudia Saad Magalhaes; Tamás Constantin; Joyce E Davidson; Bo Magnusson; Ricardo Russo; Luca Villa; Mariangela Rinaldi; Howard Rockette; Peter A Lachenbruch; Frederick W Miller; Jiri Vencovsky; Nicolino Ruperto
Journal:  Arthritis Rheumatol       Date:  2017-04-06       Impact factor: 10.995

8.  A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis management.

Authors:  L Grine; M de la Brassinne; P-D Ghislain; T Hillary; J Lambert; S Segaert; F Willaert; J Lambert
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-01-02       Impact factor: 6.166

9.  National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study.

Authors:  Rosa Parisi; Ireny Y K Iskandar; Evangelos Kontopantelis; Matthias Augustin; Christopher E M Griffiths; Darren M Ashcroft
Journal:  BMJ       Date:  2020-05-28

10.  Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study.

Authors:  Luigi Francesco Iannone; Luigi Bennardo; Caterina Palleria; Roberta Roberti; Caterina De Sarro; Maria Diana Naturale; Stefano Dastoli; Luca Donato; Antonia Manti; Giancarlo Valenti; Domenico D'Amico; Santo D'Attola; Adele Emanuela De Francesco; Vincenzo Bosco; Eugenio Donato Di Paola; Steven Paul Nisticò; Rita Citraro; Emilio Russo; Giovambattista De Sarro
Journal:  PLoS One       Date:  2020-11-03       Impact factor: 3.240

View more
  1 in total

1.  Moderate Psoriasis in Clinical Practice: French Expert Consensus Using a Modified Delphi Method.

Authors:  Marie-Aleth Richard; François Aubin; Nathalie Beneton; Anne Bouloc; Anne-Claire Bursztejn; Vincent Descamps; Denis Jullien
Journal:  Adv Ther       Date:  2022-09-16       Impact factor: 4.070

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.